Selected research
Industry Research
Angiotensin Receptor Blockers (ARBs) Industry Research Report 2026
Market perspective
The global Angiotensin Receptor Blockers (ARBs) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Angiotensin Receptor Blockers (ARBs) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Angiotensin Receptor Blockers (ARBs) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Angiotensin Receptor Blockers (ARBs) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Angiotensin Receptor Blockers (ARBs) include Teva Pharmaceutical, Sanofi, Jhonson and Johnson, Novartis, Merck, Eli Lilly, Pfizer, GSK and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Angiotensin Receptor Blockers (ARBs) market in terms of revenue (US$ million) and, where applicable, sales volume (k tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Angiotensin Receptor Blockers (ARBs) Market by Company
Teva Pharmaceutical
Sanofi
Jhonson and Johnson
Novartis
Merck
Eli Lilly
Pfizer
GSK
Bayer
Bristol-Myers Squibb
Astra Zeneca
Angiotensin Receptor Blockers (ARBs) Segment by Type
Valsartan
Telmisartan
Losartan
Irbesartan
Olmesartan
Azilsartan
Angiotensin Receptor Blockers (ARBs) Segment by Application
Cardiovascular Diseases
Kidney Diseases
Hypertension
Other
Angiotensin Receptor Blockers (ARBs) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angiotensin Receptor Blockers (ARBs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Angiotensin Receptor Blockers (ARBs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angiotensin Receptor Blockers (ARBs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Angiotensin Receptor Blockers (ARBs) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Angiotensin Receptor Blockers (ARBs) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Angiotensin Receptor Blockers (ARBs) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Valsartan
- Telmisartan
- Losartan
- Irbesartan
- Olmesartan
- Azilsartan
Applications
- Cardiovascular Diseases
- Kidney Diseases
- Hypertension
- Other
Companies covered
- Teva Pharmaceutical
- Sanofi
- Jhonson and Johnson
- Novartis
- Merck
- Eli Lilly
- Pfizer
- GSK
- Bayer
- Bristol-Myers Squibb
- Astra Zeneca
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Angiotensin Receptor Blockers (ARBs) Market Size (2021-2032)
- 2.2.2 Global Angiotensin Receptor Blockers (ARBs) Sales (2021-2032)
- 2.2.3 Global Angiotensin Receptor Blockers (ARBs) Market Average Price (2021-2032)
- 2.3 Angiotensin Receptor Blockers (ARBs) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Valsartan
- 2.3.3 Telmisartan
- 2.3.4 Losartan
- 2.3.5 Irbesartan
- 2.3.6 Olmesartan
- 2.3.7 Azilsartan
- 2.4 Angiotensin Receptor Blockers (ARBs) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Cardiovascular Diseases
- 2.4.3 Kidney Diseases
- 2.4.4 Hypertension
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Angiotensin Receptor Blockers (ARBs) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Angiotensin Receptor Blockers (ARBs) Sales (k tons) of Manufacturers (2021-2026)
- 3.3 Global Angiotensin Receptor Blockers (ARBs) Revenue of Manufacturers (2021-2026)
- 3.4 Global Angiotensin Receptor Blockers (ARBs) Average Price by Manufacturers (2021-2026)
- 3.5 Global Angiotensin Receptor Blockers (ARBs) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Angiotensin Receptor Blockers (ARBs), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Angiotensin Receptor Blockers (ARBs), Product Type & Application
- 3.8 Global Manufacturers of Angiotensin Receptor Blockers (ARBs), Established Date
- 3.9 Global Angiotensin Receptor Blockers (ARBs) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceutical
- 4.1.1 Teva Pharmaceutical Company Information
- 4.1.2 Teva Pharmaceutical Business Overview
- 4.1.3 Teva Pharmaceutical Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceutical Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 4.1.5 Teva Pharmaceutical Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Jhonson and Johnson
- 4.3.1 Jhonson and Johnson Company Information
- 4.3.2 Jhonson and Johnson Business Overview
- 4.3.3 Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 4.3.5 Jhonson and Johnson Recent Developments
- 4.4 Novartis
- 4.4.1 Novartis Company Information
- 4.4.2 Novartis Business Overview
- 4.4.3 Novartis Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novartis Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 4.4.5 Novartis Recent Developments
- 4.5 Merck
- 4.5.1 Merck Company Information
- 4.5.2 Merck Business Overview
- 4.5.3 Merck Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 4.5.5 Merck Recent Developments
- 4.6 Eli Lilly
- 4.6.1 Eli Lilly Company Information
- 4.6.2 Eli Lilly Business Overview
- 4.6.3 Eli Lilly Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Eli Lilly Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 4.6.5 Eli Lilly Recent Developments
- 4.7 Pfizer
- 4.7.1 Pfizer Company Information
- 4.7.2 Pfizer Business Overview
- 4.7.3 Pfizer Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pfizer Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 4.7.5 Pfizer Recent Developments
- 4.8 GSK
- 4.8.1 GSK Company Information
- 4.8.2 GSK Business Overview
- 4.8.3 GSK Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 GSK Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 4.8.5 GSK Recent Developments
- 4.9 Bayer
- 4.9.1 Bayer Company Information
- 4.9.2 Bayer Business Overview
- 4.9.3 Bayer Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Bayer Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 4.9.5 Bayer Recent Developments
- 4.10 Bristol-Myers Squibb
- 4.10.1 Bristol-Myers Squibb Company Information
- 4.10.2 Bristol-Myers Squibb Business Overview
- 4.10.3 Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 4.10.5 Bristol-Myers Squibb Recent Developments
- 4.11 Astra Zeneca
- 4.11.1 Astra Zeneca Company Information
- 4.11.2 Astra Zeneca Business Overview
- 4.11.3 Astra Zeneca Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Astra Zeneca Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 4.11.5 Astra Zeneca Recent Developments
5 Global Angiotensin Receptor Blockers (ARBs) Market Scenario by Region
- 5.1 Global Angiotensin Receptor Blockers (ARBs) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Angiotensin Receptor Blockers (ARBs) Sales by Region: 2021-2032
- 5.2.1 Global Angiotensin Receptor Blockers (ARBs) Sales by Region: 2021-2026
- 5.2.2 Global Angiotensin Receptor Blockers (ARBs) Sales by Region: 2027-2032
- 5.3 Global Angiotensin Receptor Blockers (ARBs) Revenue by Region: 2021-2032
- 5.3.1 Global Angiotensin Receptor Blockers (ARBs) Revenue by Region: 2021-2026
- 5.3.2 Global Angiotensin Receptor Blockers (ARBs) Revenue by Region: 2027-2032
- 5.4 North America Angiotensin Receptor Blockers (ARBs) Market Facts & Figures by Country
- 5.4.1 North America Angiotensin Receptor Blockers (ARBs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2032)
- 5.4.3 North America Angiotensin Receptor Blockers (ARBs) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Angiotensin Receptor Blockers (ARBs) Market Facts & Figures by Country
- 5.5.1 Europe Angiotensin Receptor Blockers (ARBs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2032)
- 5.5.3 Europe Angiotensin Receptor Blockers (ARBs) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Angiotensin Receptor Blockers (ARBs) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Angiotensin Receptor Blockers (ARBs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Angiotensin Receptor Blockers (ARBs) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Angiotensin Receptor Blockers (ARBs) Market Facts & Figures by Country
- 5.7.1 South America Angiotensin Receptor Blockers (ARBs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2032)
- 5.7.3 South America Angiotensin Receptor Blockers (ARBs) Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Angiotensin Receptor Blockers (ARBs) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Angiotensin Receptor Blockers (ARBs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Angiotensin Receptor Blockers (ARBs) Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Angiotensin Receptor Blockers (ARBs) Sales by Type (2021-2032)
- 6.1.1 Global Angiotensin Receptor Blockers (ARBs) Sales by Type (2021-2032) & (k tons)
- 6.1.2 Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Type (2021-2032)
- 6.2 Global Angiotensin Receptor Blockers (ARBs) Revenue by Type (2021-2032)
- 6.2.1 Global Angiotensin Receptor Blockers (ARBs) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share by Type (2021-2032)
- 6.3 Global Angiotensin Receptor Blockers (ARBs) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Angiotensin Receptor Blockers (ARBs) Sales by Application (2021-2032)
- 7.1.1 Global Angiotensin Receptor Blockers (ARBs) Sales by Application (2021-2032) & (k tons)
- 7.1.2 Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Application (2021-2032)
- 7.2 Global Angiotensin Receptor Blockers (ARBs) Revenue by Application (2021-2032)
- 7.2.1 Global Angiotensin Receptor Blockers (ARBs) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share by Application (2021-2032)
- 7.3 Global Angiotensin Receptor Blockers (ARBs) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Angiotensin Receptor Blockers (ARBs) Value Chain Analysis
- 8.1.1 Angiotensin Receptor Blockers (ARBs) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Angiotensin Receptor Blockers (ARBs) Production Mode & Process
- 8.2 Angiotensin Receptor Blockers (ARBs) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Angiotensin Receptor Blockers (ARBs) Distributors
- 8.2.3 Angiotensin Receptor Blockers (ARBs) Customers
9 Global Angiotensin Receptor Blockers (ARBs) Analyzing Market Dynamics
- 9.1 Angiotensin Receptor Blockers (ARBs) Industry Trends
- 9.2 Angiotensin Receptor Blockers (ARBs) Industry Drivers
- 9.3 Angiotensin Receptor Blockers (ARBs) Industry Opportunities and Challenges
- 9.4 Angiotensin Receptor Blockers (ARBs) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst